Somnomed Ltd (SOM) - Total Assets
Based on the latest financial reports, Somnomed Ltd (SOM) holds total assets worth AU$79.90 Million AUD (≈ $56.53 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SOM capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Somnomed Ltd - Total Assets Trend (2003–2025)
This chart illustrates how Somnomed Ltd's total assets have evolved over time, based on quarterly financial data. Check SOM cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Somnomed Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Somnomed Ltd's total assets of AU$79.90 Million consist of 53.3% current assets and 46.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 21.4% |
| Accounts Receivable | AU$11.19 Million | 13.8% |
| Inventory | AU$7.43 Million | 9.2% |
| Property, Plant & Equipment | AU$13.91 Million | 17.2% |
| Intangible Assets | AU$1.56 Million | 1.9% |
| Goodwill | AU$7.05 Million | 8.7% |
Asset Composition Trend (2003–2025)
This chart illustrates how Somnomed Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SOM company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Somnomed Ltd's current assets represent 53.3% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2025, down from 90.7% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is property, plant & equipment at 17.2% of total assets.
Somnomed Ltd Competitors by Total Assets
Key competitors of Somnomed Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Inspire Medical Systems Inc
NYSE:INSP
|
USA | $911.38 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr205.86 Million |
|
Duearity AB
ST:DEAR
|
Sweden | Skr10.84 Million |
Somnomed Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 1.81 | 2.44 |
| Quick Ratio | 1.46 | 1.52 | 2.31 |
| Cash Ratio | 0.00 | 0.80 | 1.62 |
| Working Capital | AU$18.91 Million | AU$18.64 Million | AU$22.36 Million |
Somnomed Ltd - Advanced Valuation Insights
This section examines the relationship between Somnomed Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 1.06 |
| Asset Growth Rate (YoY) | 16.0% |
| Total Assets | AU$80.97 Million |
| Market Capitalization | $86.03 Million USD |
Valuation Analysis
Above Book Valuation: The market values Somnomed Ltd's assets above their book value (1.06x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Somnomed Ltd's assets grew by 16.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Somnomed Ltd (2003–2025)
The table below shows the annual total assets of Somnomed Ltd from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$80.97 Million ≈ $57.29 Million |
+16.00% |
| 2024-06-30 | AU$69.80 Million ≈ $49.39 Million |
+11.70% |
| 2023-06-30 | AU$62.49 Million ≈ $44.22 Million |
+7.57% |
| 2022-06-30 | AU$58.09 Million ≈ $41.10 Million |
+3.43% |
| 2021-06-30 | AU$56.17 Million ≈ $39.74 Million |
-8.96% |
| 2020-06-30 | AU$61.69 Million ≈ $43.65 Million |
+77.53% |
| 2019-06-30 | AU$34.75 Million ≈ $24.59 Million |
-23.95% |
| 2018-06-30 | AU$45.70 Million ≈ $32.33 Million |
+10.88% |
| 2017-06-30 | AU$41.21 Million ≈ $29.16 Million |
+1.94% |
| 2016-06-30 | AU$40.43 Million ≈ $28.60 Million |
+45.68% |
| 2015-06-30 | AU$27.75 Million ≈ $19.64 Million |
+44.97% |
| 2014-06-30 | AU$19.14 Million ≈ $13.54 Million |
+4.59% |
| 2013-06-30 | AU$18.30 Million ≈ $12.95 Million |
+48.66% |
| 2012-06-30 | AU$12.31 Million ≈ $8.71 Million |
+40.99% |
| 2011-06-30 | AU$8.73 Million ≈ $6.18 Million |
+11.46% |
| 2010-06-30 | AU$7.83 Million ≈ $5.54 Million |
+29.74% |
| 2009-06-30 | AU$6.04 Million ≈ $4.27 Million |
-13.80% |
| 2008-06-30 | AU$7.00 Million ≈ $4.96 Million |
+49.07% |
| 2007-06-30 | AU$4.70 Million ≈ $3.32 Million |
+15.47% |
| 2006-06-30 | AU$4.07 Million ≈ $2.88 Million |
-48.61% |
| 2005-06-30 | AU$7.92 Million ≈ $5.60 Million |
+1167.43% |
| 2004-06-30 | AU$624.71K ≈ $442.02K |
+429.41% |
| 2003-06-30 | AU$118.00K ≈ $83.49K |
-- |
About Somnomed Ltd
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product desig… Read more